Home / Market News / $BIAF
fiscal.ai Corporate Catalyst Impact 75/100 ● positive

bioAffinity Technologies Reports Third Quarter 2026 Financial Results

Nov 7, 2026, 2:15 PM UTC · Primary ticker $BIAF

bioAffinity Technologies reported Q3 2026 financial results, including revenue of $1.1 million and a net loss of $5.3 million. Despite the loss, the company saw significant year-over-year growth in CyPath Lung test sales and total test revenue, indicating progress in commercialization efforts.

bioAffinity Technologies reported its third-quarter 2026 financial results, revealing a net loss of $5.3 million despite revenue of $1.1 million. While the net loss is a negative, the significant doubling of CyPath Lung test sales and a 79% increase in total test revenue for the first nine months of the year compared to 2025 are positive indicators of commercial progress and market adoption for their key product. This matters because it shows the company is growing its core business, even if profitability is still a challenge. The short-term implication for traders is a mixed signal: the loss might cause some downward pressure, but the strong sales growth could attract investors looking for long-term potential. A key opportunity is monitoring future sales growth and the impact of their expanding clinical study sites on market penetration.

$BIAF negative Reported net loss, but revenue growth is positive.
Source: fiscal.ai
Join the waitlist for full signal validation →

Not financial advice. AI-generated analysis for informational purposes only.